Theradiag Receives Frost & Sullivan 2015 European Theranostics Product Leadership Award

Regulatory News:

Theradiag (Paris:ALTER) (ISIN: FR0004197747, Ticker: ALTER), a company specializing in theranostics and in vitro diagnostics, announced today that is has been awarded the Frost & Sullivan 2015 European Theranostics Product Leadership Award for its LISA TRACKER range.

Frost & Sullivan’s Best Practice Awards independently recognize companies for demonstrating outstanding achievement and superior performance in a given technology and market for their visionary innovation, leadership, technology, and product development.

"Frost & Sullivan's analysis confirms that Theradiag has achieved exceptional growth in the sales of its theranostics products. The company’s high growth has been driven by strong sales of its LISA TRACKER products. The company’s strategic focus to stick to high-value theranostics products paid off, leading to international sales.” commented Srinivas Sashidhar, healthcare Industry analyst at Frost & Sullivan.

"Theradiag is an expert partner for developing biological diagnosis and monitoring kit. As a fully integrated company, it possesses an organized, integrated expertise, from R&D to distribution. Frost & Sullivan's research reveals that unlike its competitors, Theradiag is one of the few companies with the potential to launch diagnostic solutions in less than 12 months. This integrated strength makes Theradiag a preferred partner for its customers in custom development and commercialization.” continued Sashidhar.

Michel Finance, CEO of Theradiag concludes: « We are honored to have been recognized with the Product Leadership Award. It speaks to our commitment to innovation in theranostics, which has allowed us to remain ahead of our competitors in developing new theranostics kits and to provide the best treatments to patients. Frost & Sullivan applauds our leadership in the sector, and rewards the work of our teams.”

Frost & Sullivan’s report is available at the following address:
http://www.theradiag.com/fr/files/2015/05/Theradiag-Frost-Sullivan-May-2015.pdf

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

• The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
• The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organisation prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us: Start the discussion

Join Us: Join our community

Subscribe: Newsletter on "the next big thing"

Register: Gain access to visionary innovation

About Theradiag
Capitalizing on its expertise in the distribution, development and manufacturing of in vitro diagnostic tests, Theradiag innovates and develops theranostics tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases, cancer and AIDS. Theradiag notably markets the Lisa Tracker range (CE marked), which is a comprehensive multiparameter theranostic solution for patients with autoimmune diseases treated with biotherapies. With its subsidiary Prestizia, Theradiag is developing new biomarkers based on microRNAs for the diagnosis and monitoring of rectal cancer and HIV/AIDS. Theradiag is thus participating in the development of "customized treatment”, which favors the individualization of treatments, the evaluation of their efficacy and the prevention of drug resistance. The Company is based in Marne-la-Vallée, near Paris, and in Montpellier, and has over 70 employees.

For more information about Theradiag, please visit our website: www.theradiag.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20150526005949/en/